Join the 'Rhabdomyosarcoma' group to help and get support from people like you.
Posted 2 Dec 2016 by Drugs.com
FRIDAY, Dec. 2, 2016 – Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but difficult to treat if they are advanced and have spread to other parts of the body, the researchers said. "Soft tissue sarcomas represent a rare group of malignant tumors. Despite the use of surgery, radiotherapy and chemotherapy to treat the tumor in the localized region in which it started, up to 40 percent of patients will develop recurrence with cancer cells spreading to other parts of the body," said researcher Antoine Italiano. He heads the early phase trials and sarcoma units at Institut Bergonie in Bordeaux, France. His study found that the combination of a new cancer drug called GDC-0575 with the existing cancer drug gemcitabine ... Read more
Posted 19 Oct 2016 by Drugs.com
WEDNESDAY, Oct. 19, 2016 – Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons. Lartruvo has been sanctioned for use with the chemotherapy drug doxorubicin in cases that cannot be treated with radiation or surgery, the FDA said Wednesday in a news release. More than 12,000 new cases of soft-tissue sarcoma are projected to be diagnosed this year and nearly 5,000 people are likely to die from the disease, the agency said, citing estimates from the U.S. National Cancer Institute. Lartruvo is designed to block cell receptors that fuel tumor growth, the FDA said. The drug was evaluated in clinical trials involving 133 people with soft-tissue carcinomas. Average survival among people who took Lartruvo and doxorubicin was 8.2 months, ... Read more
Posted 23 Jul 2015 by Drugs.com
THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more
Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Femara, Lupron Depot, Gleevec, Rituxan, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer